Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis

• Published in: Clinical research in cardiology Vol. 111; no. 7; pp. 827 - 837
• Main Authors: Nano, Nejva, Aytekin, Alp, Ndrepepa, Gjin, Seguchi, Masaru, Bresha, Jola, Alvarez Covarrubias, Hector Alfonso, Nicol, Philipp, Lenz, Tobias, Lahu, Shqipdona, Gewalt, Senta, Voll, Felix, Rheude, Tobias, Wiebe, Jens, Schunkert, Heribert, Kufner, Sebastian, Cassese, Salvatore, Joner, Michael, Kastrati, Adnan, Xhepa, Erion
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2022; Springer Nature B.V
• Subjects: Calcium-binding protein; Cardiology; Drug delivery; Implants; Inhomogeneity; Medicine; Medicine & Public Health; Optical properties; Original Paper; Patients; Restenosis; Stents; Subgroups; Troponin; Troponin T; Periprocedural myocardial injury; Drug-eluting balloon; In-stent restenosis; Optical coherence tomography; Neointimal characterization; Drug-eluting stent
• ISSN: 1861-0684; 1861-0692
• DOI: 10.1007/s00392-022-02024-z

Aims Aim of the present study was to investigate the impact of increasing neointimal inhomogeneity and neoatherosclerosis as well as of treatment modality of in-stent restenosis (ISR) on the occurrence of periprocedural myocardial injury (PMI). Methods and results Patients with normal or stable/falling increased baseline high-sensitivity troponin T (hs-cTnT) undergoing intravascular optical coherence tomography (OCT) and subsequent percutaneous coronary intervention (PCI) of ISR by means of drug-coated balloon (DCB) or drug-eluting stent (DES) were included. Overall, 128 patients were subdivided into low ( n  = 64) and high ( n  = 64) inhomogeneity groups, based on the median of distribution of non-homogeneous quadrants. No significant between-group differences were detected in terms of hs-cTnT changes (28.0 [12.0–65.8] vs. 25.5 [9.8–65.0] ng/L; p  = 0.355), or the incidence of major PMI (31.2 vs. 31.2%; p  = 1.000). Similarly, no differences were observed between DCB- and DES-treated groups in terms of hs-cTn changes (27.0 [10.0–64.0] vs. 28.0 [11.0–73.0] ng/L; p = 0.795), or the incidence of major PMI (28.9 vs. 35.6%; p  = 0.566). Additionally, no significant interaction was present between optical neointimal characteristics and treatment modality in terms of changes in hs-cTnT ( P int  = 0.432). No significant differences in PMI occurrence were observed between low and high neoatherosclerosis subgroups. Conclusions In patients undergoing PCI for ISR, there was no association between increasing neointimal inhomogeneity, or increasing expression of neoatherosclerotic changes and occurrence of PMI. PMI occurrence was not influenced by the treatment modality (DCB vs. DES) of ISR lesions, a finding that supports the safety of DCB treatment for ISR. Graphical abstract